학술논문

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Document Type
journal article
Source
Journal of Clinical Oncology; 12/10/2020, Vol. 38 Issue 35, p4184-4193, 11p
Subject
Language
ISSN
0732183X